Array Biopharma: Phase I Data & IND

Two fantastic tidbits emerging out of Array Biopharma, Inc. (NASDAQ: ARRY) headquarters:

• Array has filed an Investigational New Drug application for ARRY-797 with the FDA and is now able to proceed with human clinical studies. ARRY-797 is a potent, selective, orally active inhibitor of p38 MAP kinase and has demonstrated good tolerability and significant efficacy in preclinical models of human inflammatory diseases.

• Array will be presenting data from a Phase 1 trial of AZD6244 (ARRY-142886), a novel MEK inhibitor, at the 18th Annual EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics to be held from November 7-10, 2006 in Prague, Czech Republic. AZD6244 has shown tumour suppressive activity in multiple pre-clinical models of human cancer including melanoma, pancreatic, colon, lung, and breast cancers.

Finally, Array will be reporting quarter end financial results today, 6 November, at market close. Listen to the conference call: (800) 310-6649